Challenges in the clinical assessment of novel tuberculosis drugs

Advanced Drug Delivery Reviews
Kelly E DooleyMichael Hoelscher

Abstract

To tackle the global TB epidemic effectively, novel treatment strategies are critically needed to shorten the duration of TB therapy and treat drug-resistant TB. Drug development for TB, stymied for decades, has enjoyed a renaissance over the past several years. However, the development of new TB regimens is hindered by the limitations in our understanding and use of preclinical models; the paucity of accurate, early surrogate markers of cure, and challenges in untangling the individual contributions of drugs to multidrug regimens in a complex, multi-compartment disease. Lack of profit motive, advocacy, and imagination has contributed mightily to the dearth of drugs we have on the shelf to treat this ancient disease. Areas that will speed the development of new regimens for TB include novel murine and in vitro pharmacodynamics models, clinical endpoints that are not culture-based, innovative clinical trial designs, and an infusion of much-needed funding.

Citations

Aug 8, 2018·The Indian Journal of Medical Research·Amit Kumar Singh, Umesh D Gupta
Feb 28, 2020·PLoS Medicine·Christian LienhardtTereza Kasaeva
Sep 13, 2016·Biomolecules·Shiying WuLeif A Kirsebom
Apr 9, 2020·BMC Microbiology·Philip Kam Weng KwanNicholas I Paton
Apr 8, 2020·Journal of Medicinal Chemistry·Vadim MakarovSean Ekins

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antiparasitics

Antiparasitics are medications which are indicated for the treatment of parasitic diseases. Discover the latest research on antiparasitics here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Related Papers

Nature Reviews. Drug Discovery
Alimuddin I ZumlaAndrew J Nunn
Public Health Nutrition
Milla McLachlan, James Garrett
Current Opinion in Pulmonary Medicine
Andrew J NunnIbrahim Abubakar
American Journal of Respiratory and Critical Care Medicine
Jakko van IngenCharles L Daley
© 2021 Meta ULC. All rights reserved